James S Blachly, MD
James S Blachly, MD
Assistant Professor of Internal Medicine, The Ohio State University
Zweryfikowany adres z osumc.edu
Cytowane przez
Cytowane przez
Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL
JA Woyach, AS Ruppert, NA Heerema, W Zhao, AM Booth, W Ding, ...
New England Journal of Medicine 379 (26), 2517-2528, 2018
BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
JA Woyach, AS Ruppert, D Guinn, A Lehman, JS Blachly, A Lozanski, ...
Journal of Clinical Oncology 35 (13), 1437-1443, 2017
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
MR Grever, O Abdel-Wahab, LA Andritsos, V Banerji, J Barrientos, ...
Blood, The Journal of the American Society of Hematology 129 (5), 553-560, 2017
Expression and prognostic impact of lncRNAs in acute myeloid leukemia
R Garzon, S Volinia, D Papaioannou, D Nicolet, J Kohlschmidt, PS Yan, ...
Proceedings of the National Academy of Sciences 111 (52), 18679-18684, 2014
BRD4 profiling identifies critical chronic lymphocytic leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor
HG Ozer, D El-Gamal, B Powell, ZA Hing, JS Blachly, B Harrington, ...
Cancer discovery 8 (4), 458-477, 2018
Targeting PI 3‐kinase (PI 3 K), AKT and m TOR axis in lymphoma
JS Blachly, RA Baiocchi
British journal of haematology 167 (1), 19-32, 2014
Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies
AK Eisfeld, J Kohlschmidt, K Mrózek, JS Blachly, CJ Walker, D Nicolet, ...
Leukemia 32 (6), 1338-1348, 2018
Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations
J Woyach, Y Huang, K Rogers, SA Bhat, MR Grever, A Lozanski, ...
Blood 134, 504, 2019
The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia
AK Eisfeld, K Mrózek, J Kohlschmidt, D Nicolet, S Orwick, CJ Walker, ...
Leukemia 31 (10), 2211-2218, 2017
Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged< 60 years
AK Eisfeld, J Kohlschmidt, A Mims, D Nicolet, CJ Walker, JS Blachly, ...
Leukemia 34 (12), 3215-3227, 2020
Emerging drug profile: cyclin-dependent kinase inhibitors
JS Blachly, JC Byrd
Leukemia & lymphoma 54 (10), 2133-2143, 2013
Acalabrutinib plus obinutuzumab in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia
JA Woyach, JS Blachly, KA Rogers, SA Bhat, M Jianfar, G Lozanski, ...
Cancer discovery 10 (3), 394-405, 2020
Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A
M Bill, K Mrózek, J Kohlschmidt, AK Eisfeld, CJ Walker, D Nicolet, ...
Proceedings of the National Academy of Sciences 117 (42), 26340-26346, 2020
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia
E Young, D Noerenberg, L Mansouri, V Ljungström, M Frick, LA Sutton, ...
Leukemia 31 (7), 1547-1554, 2017
Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically
K Mrózek, AK Eisfeld, J Kohlschmidt, AJ Carroll, CJ Walker, D Nicolet, ...
Leukemia 33 (7), 1620-1634, 2019
Quality control for RNA-Seq (QuaCRS): an integrated quality control pipeline
KW Kroll, NE Mokaram, AR Pelletier, DE Frankhouser, MS Westphal, ...
Cancer informatics 13, CIN. S14022, 2014
HDAC inhibition induces microRNA-182, which targets RAD51 and impairs HR repair to sensitize cells to sapacitabine in acute myelogenous leukemia
TH Lai, B Ewald, A Zecevic, C Liu, M Sulda, D Papaioannou, R Garzon, ...
Clinical cancer research 22 (14), 3537-3549, 2016
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia
KA Rogers, LA Andritsos, L Wei, EM McLaughlin, AS Ruppert, ...
Blood, The Journal of the American Society of Hematology 137 (25), 3473-3483, 2021
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia
B Bhatnagar, AK Eisfeld, D Nicolet, K Mrózek, JS Blachly, S Orwick, ...
British journal of haematology 175 (2), 226-236, 2016
PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL
D El-Gamal, K Williams, TD LaFollette, M Cannon, JS Blachly, Y Zhong, ...
Blood, The Journal of the American Society of Hematology 124 (9), 1481-1491, 2014
Nie można teraz wykonać tej operacji. Spróbuj ponownie później.
Prace 1–20